Member Info for chester18

Flatliners

If the WCE lab results are of a really high grade it bodes very well for the progression towards digging some out of the ground.

If that news was greeted by a substantial rise in the WCE share price, why would UFO not also rise some percentage or two ?

Good time for West Coast to reveal those ‘drill core’ lab results. The fact that they raised 3.2 million AUD does suggest that they will be better than just ok.

Silver now over $90 is amazing.

GLA

The share price has been cycled through 9p to 10.5p for over a year. Many potential news moments in 2025 that could have moved the price back towards 14p but was heavily sold into, every time we moved anywhere near 10.5p.

Therefore this flourish that has not been generated by actual news is probably venting some of the loose hands hold stock at 10p and below.

The success of achieving the FDA ‘IND’ will be the kind of news that really moves the SP to a much higher level. That then folds into the anticipation of a partnership / deal.

FOMO will definitely kick in at that point.

Right now is the opportunity to build a position ready for those possible jumps in value.

Inanaco has always professed “it’s not the price of the shares it’s how many you are holding when that critical news lands” ……

What a great start to the week. With all the potential value stored up in Scancell, where should the price be, pending news of our IND submission ?

Positive clearance by the FDA states very clearly that the SCOPE trial has been conducted to a high standard and the data is good enough to conduct part of the Ph3 trial in the USA.

The FDA is still held in high esteem even given the current turbulence. Our CEO said that the UK and European Regulatory bodies accept that if the data is good enough for the FDA then it’s got a very high probability of passing all their criteria.

So where should we be ‘share price’ wise if it were not for someone having to sell down 25 million shares and if we were actually priced relevant to our potential future markets ?

Is 12.25p ( £127 million Market Cap ) a fair starting point or should we already be twice that value just based on what is public knowledge of our data, the shown 24% improvement on SOC ( Standard of Care ) and the heralded re-emergence of Bio-Tech M&A in 2026 ?

I think this post would be classed as ‘Happy Clappy’ if it were not for the emerging realities of ‘Patent end of life pressure’ and the announcement by big pharma that they have roughly $200billion ready to spend on solid future assets.

I consider Scancell to fit that description perfectly well.

If the brakes are now off I would expect some accumulation to happen as we approach the day when we’re told we have passed any of the FDA’s objections / amendments to our iScib1+ IND.

At that point Partnering or straight out deal making can be seriously discussed. We can also expect a ModiTope Trial update soon after that RNS and news about our submissions to the MHRA and EMA to boot.

Scancell could become a major news story in less than 6 weeks.

One of my favourites :

“If this blows up it’ll go ballistic”

Hi violindog

That was well worth reading and does show that Scancell could not be heading into a Phase 3 trial at a better time.

Pharma is actively looking for solid assets and Scancell could be about to become exactly what they are looking for.

Good points KonarA

Let’s hope that it’s already landed in the FDA’s ‘in tray’ . 👊👊

The only thing I’ll say is that the ‘end of the year’ comment has created expectation, warranted or not.

The reality may be that it does take a while before a final submission is made. Also it could already be done and dusted.

To promise a thing and then just leave it hanging is not a good policy at any time.

I’m also sure the company and all the staff involved are working flat out to get the IND over the line. 👊👊

Hi EE

Makes you wonder where the price would be if we didn’t have to wade through all these loose shares.

On the other side of this deluge the sp could climb very quickly on news 👊👊

No, it is irrelevant looking back and wishing I’d invested differently. The clue is in the word ‘invested’.

Without TIME Scancell would not be in the position of submitting an IND for ISCIB1+.

We’ve all had the chance to take back part or all of our money, I did at 24p and bought Greatland Gold. When that went from 1.8p to 20p I took that back and doubled my Scancell holding.

Investment does not imply being static.

So my faith in Scancell has persisted and I’m looking forward to 2026 and the SCOPE trial but my journey is all about Moditope.

Good luck everyone this year has great potential to see huge progress for Scancell.

The thing is RuckRover, the reality is that all the levers that could create a ‘Pivotel Year’ are now in place.

Toxicity passed, Ph1 passed, Ph2 passed, Durability of Modi1 passed and FDA clearance a very high probability.

So let’s dispense with the years gone bye because they are now irrelevant it’s 2026 and this has every chance of defining Scancell’s technological excellence.

Hi douve87

Only sure thing is the submission of the SCOPE Trial ‘IND’ to the FDA. Our CEO Phil said they were trying their best to complete the submission by the last few days of 2025.

Obviously there was more to achieve than he expected. Other than ‘left field’ news I think the Modi-1 update will be February or March but news about GenMab of GlyMab Theraputics could land at any time.

All the best for 2026 👍

All the best to each and everyone who posts or just reads the conversations or messages on this board.

2026 does have the potential to be a game changer for Scancell. Only 25% of BioTech start ups ever file an IND and only 10% complete a Phase3 and achieve an approval for a drug or treatment.

Scancell are to start their SCOPE Trial ph3 around Q3 or early Q4 but the questions of ‘Who With’ and ‘How Funded’ are part of why 2026 could be so rewarding for all shareholders.

The amazing fact is that we have both the ModiTope Trial and GlyMab Theraputics Ltd in the mix to provide even greater success during 2026.

So good luck and good health everyone and I also include any doubters or doomies, where would we be without you.

Chester 👊

Silver just touched $77………

Has to have some impact in the value of Alien Metals !!

Same as Matt, Merry Christmas everyone.

We’ve seen plenty of occasions where we thought Scancell were about to hit the mythical ‘inflection point’ and see the SP rise and then push on to higher levels. In the past 5 years we’ve had rises to 20p, 24p and 28p only to see them slowly dissolve back to current levels.

2026 is definitely going to be a whole different standard. Remember that we have multiple shots on goal, so what happens if they all go in 🤔

There will be a solid rise in 2026, beginning with the submission of an IND to the FDA and followed by submissions to the EMA and MHRA.

Good luck All.

Have a Great Christmas as we look forward to a very exciting period of news regarding all things Scancell. 👍👍

No mention of Scancell in that article, just shows that we are still not on everybodies radar.

FDA approval of our IND should start to push Scancell’s innovations into the consciousness of the immuno-oncology mainstream.

Submission of our IND is the starting point and that should happen in the next week or two.

SCIB1 Mono therapy has got a very solid back story with very impressive results in stage 3 & 4 Resected Melanoma cancer.

Even though it was only 16 patients, that early trial should have been bankrolled by a visionary large pharma co, but Cancer Vaccines and Electroporation were not liked at that time.

Now though everything is lining up for Scancell’s platforms to become the ‘disruptive kid on the block’.

Immunobody ✔️

Moditope ✔️

AvidiMab ✔️

GlyMabs ✔️

All four could be mainstream therapies in the not too distant future.

GLA.

Hi MBUski

There is no hold up. The Scancell staff are 100% engaged in progressing the SCOPE trial by submitting an IND to the FDA. That presentation you missed was both pragmatic and informative.

The ModiTope trial is progressing and the data is building but our CEO was very clear that he wants impact when that data is released.

On balance it is much better to wait than rush out results when a few more months could really enthuse the large pharma company's.

Timeline from here :

IND Sumbmitted to the FDA.

FDA response within 30 to 60 days.

GenMab update Q1 26

Modi1 update Q1 26

If the FDA response is positive we can move towards the Registration Trial and at that point we can expect a partnership to be announced.

This week’s news is fantastic and the future worth of the company is looking extremely positive. So why is the SP still on hold ?

One explanation is that every time we see a strong uplift in the SP millions of shares are dumped. We know this has nothing to do with how the company is progressing and it is more about a poorly judged investment fund having to sell out. But this has completely floored sentiment and ruined any confidence in buying above 10 / 11p.

The IND submission will be the start of a new era for Scancell. Will it push the SP much higher ? I expect it will allow sentiment to slowly return with a focus on what the FDA say in the 30 days allotted for a response,

If the FDA accept the IND then we really are into new territory and sentiment will quickly turn very positive. The addition of a partnership/ deal will remove the last remnants of doubt and the share price will begin to rise towards fair value. In my book a minimum of 20p at this stage.

That’s a market cap roughly at £220M solely on the potential of iSCIB1+.

Where we go from there will be decided by how good the Modi1 data is, how committed GenMab are to our GlyMabs and how big a deal is done to secure the SCOPE ( 433 patient ) Phase III reg trial.

We are absolutely on the precipice of seeing Scancell’s Immunobody, Moditope and GlyMab platforms ‘positively’ re-value the company.

A clinical trial IND (Investigational New Drug) is an application submitted to the FDA by a pharmaceutical company to obtain permission to start human clinical trials for a new drug. This application includes data on the drug's safety, manufacturing information, and detailed protocols for the proposed studies to ensure that participants are not exposed to unnecessary risks